Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | DGKA | P23743 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | FAAH | O00519 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | CNR2 | P34972 | 1/20 | 0.68 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10492134 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL16431952 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL480475 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384463 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384469 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Diolein SCHEMBL160985 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL2179183 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8384789 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL21436106 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8750559 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129333-A1 | LIPID NANOPARTICLES HAVING NON-POLAR LIPIDS FOR NUCLEIC ACID DELIVERY TO THE LIVER | NANOVATION THERAPEUTICS INC. (CA) | 2025-06-26 | — | — | WO | claimed |
| WO-2025129333-A1 | LIPID NANOPARTICLES HAVING NON-POLAR LIPIDS FOR NUCLEIC ACID DELIVERY TO THE LIVER | NANOVATION THERAPEUTICS INC. (CA) | 2025-06-26 | — | — | WO | disclosed |
| CN-115023223-A | Methods and compositions for treating oral diuretic refractory edema | 雷斯乔制药有限责任公司 | 2022-09-06 | — | — | CN | disclosed |
| US-11318215-B2 | Composition for gene delivery comprising chitosan and liquid crystal formation material | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-05-03 | — | — | US | disclosed |
| CN-106459495-B | Microtextured film with improved tactile impression and/or reduced noise perception | 宝洁公司 | 2020-01-31 | — | — | CN | disclosed |
| US-7195901-B1 | Diacylglycerol acyltransferase and its use to preferentially incorporate fatty acids into diacylglycerol | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2007-03-27 | — | — | US | disclosed |
| EP-0381057-A2 | Chemical composition for external application | Sansho Seiyaku Co., Ltd. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318215-B2 | Composition for gene delivery comprising chitosan and liquid crystal formation material | CALCOCO2, CHIA, CAB39 | PRKCA 1597/4885PRKCE 3350/4885PRKCQ 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.